POSTPARTUM MEDICAL REHABILITATION OF OBESE WOMEN


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The postpartum period is limited to 42 days, while the rehabilitation of a woman takes an average of 1 year. When implementing reproductive plans, obese women often face the worsening course of somatic disease and the development of a number of new diseases. Objective. To determine the effectiveness of a comprehensive postpartum rehabilitation program implemented for 12 months in obese women. Subjects and methods. The investigation enrolled 64 puerperas, of whom 33 were diagnosed with obesity and used a postpartum rehabilitation program. A comprehensive rehabilitation program was proposed to be used for 60 months postpartum, which included lifestyle modifications (proper nutrition, sufficient physical activity), cholecalciferol supplementation with at least 1500 IU to replenish vitamin D levels, medical correction of obesity with the combined drug Reduxin Forte for 3 months (after stopping breastfeeding), and consultations with a psychotherapist. Results. The women lost weight (by an average of 7.68 kg), improved their psychological status (there was no risk of postpartum depression; the manifestations of maternal melancholy were minimized), and every two (48.5%) patients reached the standard serum vitamin D levels. The rehabilitation program could improve the puerperas’ somatic health: the detection of non-alcoholic fatty liver disease was twice as common; there were no cases of diabetes mellitus. Conclusion. The proposed postpartum rehabilitation program has a positive impact on the body, by improving the physical, mental, somatic, and sexual health of a woman, which generally indicates a change in her quality of life.

Full Text

Restricted Access

About the authors

Elena L. MAKAROVA

City Perinatal Center, M.A. Tverye City Hospital

Email: makarova_803@mail.ru
Cand. Med. Sci., obstetrician/gynecologist Perm, Russia

Anna A. OLINA

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology; Academician Ye.A. Vagner Perm State Medical University

Email: olina29@mail.ru
Dr. Med. Sci., Professor, First Deputy Director, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology; Academician Ye.A. Vagner Perm State Medical University Perm, Russia

References

  1. Ng M., Fleming T., Robinson M., Thomson B., Graetz N., Margono C. et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 384(9945): 766-81. https://dx.doi. org/10.1016/S0140-6736(14)60460-8.
  2. Jungheim E.S., Travieso J.L., Carson K.R., Moley K.H. Obesity and reproductive function. Obstet. Gynecol. Clin. North Am. 2012; 39(4): 479-93. https://dx.doi. org/10.1016/j.ogc.2012.09.002.
  3. Stefan N., Häring H.-U., Hu FB., Schulze M.B. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013; 1(2): 152-62. https://dx.doi.org/10.1016/S2213-8587(13)70062-7.
  4. Bell J.A., Kivimaki M., Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. Obes. Rev. 2014; 15(6): 504-15. https://dx.doi.org/10.1111/obr.12157.
  5. Nguyen T., Lau D.C.W. The obesity epidemic and its impact on hypertension. Can. J. Cardiol. 2012; 28(3): 326-33. https://dx.doi.org/10.1016/j. cjca.2012.01.001.
  6. Mihalko W.M., Bergin P.F., Kelly F.B., Canale S.T. Obesity, orthopaedics, and outcomes. J. Am. Acad. Orthop. Surg. 2014; 22(11): 683-90. https://dx.doi. org/10.5435/JAAOS-22-11-683.
  7. Rennie K.L., Jebb S.A. Prevalence of obesity in Great Britain. Obes. Rev. 2005; 6(1): 11-2. https://dx.doi.org/10.1111/j.1467-789X.2005.00164.x.
  8. Макарова Е.Л., Олина А.А., Терехина Н.А. Роль комплексной программы прегравидарной подготовки женщин с ожирением в профилактике гестационных осложнений. Акушерство и гинекология. 2020; 4: 182-8.
  9. Макарова Е.Л., Падруль М.М. Ожирение и гиповитаминоз D, как фактор риска послеродовых осложнений. Пермский медицинский журнал. 2019; 36(5): 5-10.
  10. Rosenblum O., Danon G., Nestour A. Les depressions maternelles postnatales: description, psychopathologie et aspects therapeutiques. Perspect. Psychiatr. 2000; 39(3): 185-98.
  11. Rosen R.S., Brown C., Heiman J., Leiblum S.R., Meston C., Shabsigh R. et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J. Sex Marital Ther. 2000; 26(2): 191-208. https://dx.doi.org/10.1080/009262300278597.
  12. Loria P., Adinolfi L.E., Bellentani S., Bugianesi E., Grieco A., Fargion S. et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A Decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig. Liv. Dis. 2010; 42(4): 272-82. https://dx.doi. org/10.1016/j.dld.2010.01.021.
  13. Громова О.А., Торшин И.Ю. Витамин D - смена парадигмы. М.: ГЭОТАР-Медиа; 2017. 568с.
  14. Клинический протокол «Гипертензивные расстройства во время беременности, в родах, в послеродовом периоде. Преэклампсия, Эклампсия». М.; 2014.
  15. Maxwell C., Gaudet L., Cassir G., Nowik C., McLeodN.L., Jacob C.É., Walker M. Guideline No 392 - pregnancy and maternal obesity Part 2: Team planning for delivery and postpartum care. J. Obstet. Gynaecol. Can. 2019; 41(11): 1660-75. https://dx.doi.org/10.1016/j.jogc.2019.03.027.
  16. Диагностика, лечение, профилактика ожирения и ассоциированных с ним заболеваний. Национальные клинические рекомендации. СПб.; 2017: 7-10.
  17. Учамприна В.А., Романцова Т.И., Калашникова М.Ф. Комплексный подход в лечении метаболического синдрома. Ожирение и метаболизм. 2014; 1: 32-7.
  18. Мельниченко Г.А., Романцова Т.И., Журавлева М.В. Всероссийская программа безопасного снижения веса «ПримаВера». Итоги первого года проведения. Ожирение и метаболизм. 2014; 1: 62-7.
  19. Ryan D.H., Yockey S.R. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr. Obes. Rep. 2017; 6(2): 187-94. https://dx.doi. org/10.1007/s13679-017-0262-y.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies